What is your perspective on the recent results from the two ulotaront trials? Is TAAR1 still a potential target? Thanks for an excellent breakdown of KarXT, fingers crossed it becomes a helpful clinical tool!
I honestly wasn’t aware of it until seeing the recent disappointing results in the news, so I don’t have much insight.
It does demonstrate the difficulty in developing new medications for psychiatric disorders - phase 3 trials are *tough*. Particularly as we don’t have any objective illness markers and there is often a big placebo response.
It’s why I like to celebrate any successes when I see them!
I’ll add that M1 and M4 agonism may even be tapping into an important MOA of Clozapine that makes it uniquely effective. I am very excited!
Good point. That would be quite something.
What is your perspective on the recent results from the two ulotaront trials? Is TAAR1 still a potential target? Thanks for an excellent breakdown of KarXT, fingers crossed it becomes a helpful clinical tool!
I honestly wasn’t aware of it until seeing the recent disappointing results in the news, so I don’t have much insight.
It does demonstrate the difficulty in developing new medications for psychiatric disorders - phase 3 trials are *tough*. Particularly as we don’t have any objective illness markers and there is often a big placebo response.
It’s why I like to celebrate any successes when I see them!